By using a bright fluorescent particle, the researchers were able to achieve between 95 and 96 percent sensitivity for their SARS-CoV-2 tests.
The test measures changes in wavelength to quantify the presence of disease in a patient sample in about 40 minutes.
New Biomarker, Test From Wash U Team Aims to ID Patients at Higher Risk of Cardiovascular Disease
The diagnostic blood test for elevated serum fatty acid synthase detected patients at risk of chronic limb-threatening ischemia with 83 percent accuracy.
Genetic Technologies, WashU Team up to Study Breast Cancer Risk in Woman of African Descent
The Australian company is working with the Institute for Public Health in St. Louis to expand the predictive capability of its GeneType breast cancer risk test.
The company hopes to complete the trial in early 2022 and submit data to the FDA for approval of its assay, which could compete with Exact Sciences' Cologuard.